Skip to Main Content

Paper Details

Phase II study of pembrolizumab in refractory esophageal cancer with correlates of response and survival.
Journal for ImmunoTherapy of Cancer
11
2021
Author NameAffiliation
Adam J BassDana-Farber Cancer Institute
Adam J BassBroad Institute of MIT and Harvard
Adam J BassHerbert Irving Comprehensive Cancer Center, Columbia University
  • 1 - 3

Datasets

Release 1.2